Home LiteratureArticle Details
PMID: 10802692 Published · ppublish English Journal Article

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Nature medicine ·Vol. 6 ·No. 5 ·2000-05-00 ·Pages 493-5

Restifo NP

Abstract

暂无摘要

MeSH Terms
Cell Death Fas Ligand Protein Immune Tolerance Immunity, Cellular Membrane Glycoproteins/immunology Models, Immunological Transplantation Immunology/immunology Tumor Escape/immunology
Chemicals
Fas Ligand Protein Membrane Glycoproteins
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Restifo N P
National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. [email protected]
References (29)
29 references, click to expand
  1. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
    Cancer Res. 1999 Oct 15;59(20):5356-64 PMID: 10537320
  2. T cell-tumor cell: a fatal interaction?
    Cancer Immunol Immunother. 1998 Oct;47(2):65-71 PMID: 9769114
  3. Immune response and myoblasts that express Fas ligand.
    Science. 1997 Nov 14;278(5341):1322-4 PMID: 9411754
  4. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme.
    Cell. 1992 May 15;69(4):597-604 PMID: 1339309
  5. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock.
    Cell. 1995 Feb 10;80(3):401-11 PMID: 7859282
  6. Immunology. Ways around rejection.
    Nature. 1995 Oct 19;377(6550):576-7 PMID: 7566165
  7. A role for CD95 ligand in preventing graft rejection.
    Nature. 1995 Oct 19;377(6550):630-2 PMID: 7566174
  8. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.
    Nat Med. 1997 Jul;3(7):738-43 PMID: 9212099
  9. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival.
    J Exp Med. 2000 Apr 3;191(7):1209-20 PMID: 10748238
  10. Gene transfer of Fas ligand induces tumor regression in vivo.
    Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13862-7 PMID: 9391118
  11. Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection.
    Transplant Proc. 1998 Mar;30(2):538 PMID: 9532168
  12. Technical note: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies.
    J Immunol. 1998 May 1;160(9):4159-60 PMID: 9574514
  13. Chemotactic activity of soluble Fas ligand against phagocytes.
    J Immunol. 1998 Nov 1;161(9):4484-8 PMID: 9794371
  14. Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
    Cancer Res. 1999 Jan 1;59(1):59-62 PMID: 9892185
  15. Fas counter-attack--the best form of tumor defense?
    Nat Med. 1999 Mar;5(3):267-8 PMID: 10086376
  16. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
    J Immunol. 1999 Mar 15;162(6):3273-9 PMID: 10092779
  17. Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.
    Annu Rev Immunol. 1999;17:221-53 PMID: 10358758
  18. Attempts to reveal the mechanism of CD95-ligand-mediated inflammation.
    Transplant Proc. 1999 Aug;31(5):1942-3 PMID: 10455926
  19. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10.
    Melanoma Res. 1999 Jun;9(3):261-72 PMID: 10465582
  20. Do CTL kill target cells by inducing apoptosis?
    Semin Immunol. 1997 Apr;9(2):135-44 PMID: 9194224
  21. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.
    Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3943-7 PMID: 9108084
  22. Rejection of Fas ligand-expressing grafts.
    Transplant Proc. 1997 Feb-Mar;29(1-2):1092-3 PMID: 9123215
  23. Contribution of Fas ligand to cardiac allograft rejection.
    Int Immunol. 1996 Sep;8(9):1347-54 PMID: 8921411
  24. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Science. 1996 Nov 22;274(5291):1363-6 PMID: 8910274
  25. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex.
    Cell. 1996 Jun 14;85(6):817-27 PMID: 8681377
  26. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
    Science. 1996 Jul 5;273(5271):109-12 PMID: 8658177
  27. CD95 ligand in graft rejection.
    Nature. 1996 Feb 22;379(6567):682 PMID: 8602212
  28. Functional expression of Fas and Fas ligand on human gut lamina propria T lymphocytes. A potential role for the acidic sphingomyelinase pathway in normal immunoregulation.
    J Clin Invest. 1996 Jan 15;97(2):316-22 PMID: 8567950
  29. Fas ligand-induced apoptosis as a mechanism of immune privilege.
    Science. 1995 Nov 17;270(5239):1189-92 PMID: 7502042
Article Info
Journal
Nature medicine
Abbr.
Nat Med
ISSN
1078-8956
DOI
10.1038/74955
Email
[email protected]
Published
2000-05-00
Pages
493-5
Language
English
Region
United States
NLM ID
9502015
PMCID
PMC1955754
Subset
IM
Grants
Intramural NIH HHS · Z01 BC010763-01 · United States
Intramural NIH HHS · Z99 CA999999 · United States
External Links
PubMed source DOI: 10.1038/74955 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2